In terms of predictive biomarkers of disease response or resistance to FGFR pathway inhibition, FGFR dysregulation has been associated with PI3K, cyclin D1, MYC and p53 mutations in breast cancer [104]. This evidence concerns the gene CCND1 and breast carcinoma.